{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"FIERCE-22","nct_id":"NCT03123055","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fierce-22-nct03123055. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FIERCE-22","arms":[{"description":"B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.","label":"B-701 (vofatamab)","type":"EXPERIMENTAL"},{"description":"B-701 (vofatamab, 25 mg/kg \\[or the recommended Phase 2 dose if different than 25 mg/kg\\]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.","label":"B-701 (vofatamab) plus pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2019-12-01","type":"ACTUAL"},"conditions":["Locally Advanced or Metastatic Urothelial Cell Carcinoma","Urinary Bladder Disease","Urological Diseases"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"B-701","otherNames":["MFGR1877S","Vofatamab"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2020-03-18","lead_sponsor":"Rainier Therapeutics","official_title":"A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2019-12-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Dose Limiting Toxicities Within a Period of 35 Days","timeFrame":"1 year"},{"measure":"Number of Subjects Experiencing Adverse Events (AEs and SAEs)","timeFrame":"2.5 years"},{"measure":"Efficacy of B-701 (Vofatamab) Plus Pembrolizumab Measured by ORR","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2017-04-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT03123055"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fierce-22-nct03123055"}